In one paragraphArticle in Redox biochemistry and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Molly S MyersDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0001-7943-2268 Elizabeth A KosmacekDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Chia Sin LiewNebraska Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, 68588, USA.ORCID 0000-0003-0944-6423 Arpita ChatterjeeDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Melinda WojtkiewiczDepartment of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0001-8029-4536 Pooja RoyDepartment of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0009-0008-0727-1694 R Katherine HydeDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0003-2808-1749 Punita DhawanDepartment of Surgery, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
Shuo WangDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Kyle J HewittDepartment of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0003-1946-625X Cristina M FurduiDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, 27587, USA.
Rebekah L GundryDepartment of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Jean-Jack M RiethovenNebraska Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, 68588, USA.ORCID 0000-0002-2709-7880 Chi LinDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Rebecca E Oberley-DeeganDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.ORCID 0000-0002-0391-142X Funding
Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4MThe role of stress in the fetal origin of obesity and metabolic dysfunctionP20GM104320 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI ZEMPLENI, JANOS · 2014 to 2024
$24.9MTargeted mass spectrometry approaches to understand CART processing and recepter interactionsP20GM113126 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI GUO, JIANTAO · 2016 to 2025
$20.8MUse of radioprotector in rectal cancerR01CA255618 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Chi Lin, REBECCA E OBERLEY-DEEGAN · 2022 to 2026
$2.4MMnTE-2-PyP as a radioprotector in prostate cancer therapyR01CA178888 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OBERLEY-DEEGAN, REBECCA E · 2014 to 2018
$1.6MFundamental Training Program in Biochemistry and Molecular Biology ResearchT32GM153375 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Steven H Caplan, Ricia Katherine Hyde · 2024 to 2026
$949kImage-Guided Radiator InstrumentS10OD023447 · OD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OBERLEY-DEEGAN, REBECCA E · 2018 to 2018
$600kNCI NIH HHS P30 CA012197NCI NIH HHS R01 CA178888NCI NIH HHS R01 CA255618NIGMS NIH HHS P20 GM104320NIGMS NIH HHS P20 GM113126NIGMS NIH HHS T32 GM153375NIH HHS S10 OD023447
6 · The paper itselfAbstract
Colorectal cancer is a common yet survivable malignancy, partly due to the addition of chemoradiation to treatment regimens. Many patients suffer treatment-related side effects such as pain, diarrhea, and myelosuppression, and increasing tolerance of treatment has the potential to improve outcomes. BMX-001, a superoxide dismutase mimetic, is currently in clinical trials as a selective radioprotector for anal and rectal cancer; however, the mechanism by which BMX-001 exerts selective radioprotection of healthy tissue over cancer tissue, particularly when administered at physiologically achievable doses, is not well understood. BMX-001 was given before and during chemoradiation and did not interfere with chemoradiation-induced cancer cell killing in mouse models.
Indexed as
5-FUBMX-001RadiationRectal cancerROS
Identifiers
PMID42369229
PMCPMC13297990
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390